ReviewCurrent allergy and asthma reports2019
Emerging Therapeutics for Ocular Surface Disease.
Review in Current allergy and asthma reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 32 citations in OpenAlex.
- Reproxalap - A Novel Treatment Option for Allergic Conjunctivitis - A Comprehensive Narrative Review.Health science reports · 2026Article
- Advances in the Medical Management of Pediatric Blepharokeratoconjunctivitis.Advances in therapy · 2026Review
- Prevalence of ocular allergy among adults in Trinidad and Tobago: A cross-sectional study.International ophthalmology · 2025Article
- Article
- Brimonidine Eye Drops within the Reach of Children: A Possible Foe.Children (Basel, Switzerland) · 2024Article
- Therapeutic Targets in Allergic Conjunctivitis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Current Knowledge in Allergic Conjunctivitis.Turkish journal of ophthalmology · 2021Review
- Research Progress of the Application of Hypothermia in the Eye.Oxidative medicine and cellular longevity · 2020Review
- The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders.International journal of molecular sciences · 2019Review
- Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.Drugs & aging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe purpose of this article is to review treatment advances in ocular allergy that include the treatment of the various signs and symptoms of the allergic inflammatory response of the ocular surface. RECENT
findingsRecent studies have demonstrated improved pharmacological effect of topical agents with artificial tears and cold compresses; brimonidine, a new ophthalmic decongestant which has demonstrated decreased rebound conjunctivitis; and potential use of contact lens and other novel delivery instruments to increase medication retention time. Currently, there have been limited advances in novel ophthalmic treatments. Non-pharmacological interventions have demonstrated in a randomized control study that artificial tears and the use cold compresses alone or in combination with ophthalmic antihistamines can enhance the effectiveness of a traditional pharmacological therapy. The primary advances have been the start of head-to-head studies comparing various agents actively being used in the treatment of ocular allergy. In addition, there has been increasing interest in the development of novel delivery systems to increase residence time of pharmacological agents in the ocular surface such as nanoparticles, microfilms; examining novel pathways of controlling the allergic inflammatory response of the ocular surface such as modulation of cytokines, transcription factors, and immunophilins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.